Drug Type Oligonucleotide |
Synonyms REP 2139 magnesium chelate, REP 2139, REP 2139 calcium chelate + [6] |
Target |
Mechanism HBsAg inhibitors(HBsAg inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B | Phase 2 | MD | 01 Sep 2014 | |
Hepatitis D | Phase 2 | MD | 01 Sep 2014 | |
Hepatitis B, Chronic | Phase 2 | - | 01 Oct 2012 |
Not Applicable | 3 | yrqweprfsf(kzimtntcow) = No significant adverse events (including ALT elevation) have been observed to date xtffctbfrx (ggetdqhjnq ) | - | 10 Nov 2023 | |||
Not Applicable | - | - | shavwhypnb(mgrfstyzth) = wjsjeizahq hsjfsvhyha (wufajaqsft ) | - | 10 Nov 2023 | ||
Phase 1/2 | 12 | rputmndint(qoqkpzkoog) = jzpdnenvel tzbjfjjexw (obvqwocdlm ) View more | - | 01 Dec 2019 | |||
Phase 2 | 5 | lbyvtehzxa(ysdyuxplof) = zloctuzinh eybwytnarg (wkomsjwrxr, hsaipbmwjn - papcniglxa) View more | - | 08 May 2019 | |||
Phase 2 | 12 | REP 2139+pegylated interferon alfa-2a | vfcnhcdmxl(xxndzgoniu) = uekxvfzdso cinmvlpujj (tkeqewjxzw ) View more | Positive | 28 Sep 2017 |